IRIS
SOBRERO, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.619
EU - Europa 1.646
AS - Asia 570
Continente sconosciuto - Info sul continente non disponibili 9
SA - Sud America 2
Totale 7.846
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.605
UA - Ucraina 828
DE - Germania 292
FI - Finlandia 270
SG - Singapore 267
CN - Cina 260
IE - Irlanda 116
SE - Svezia 56
IT - Italia 49
TR - Turchia 39
GB - Regno Unito 19
CA - Canada 14
RU - Federazione Russa 12
EU - Europa 9
IN - India 2
BR - Brasile 1
CL - Cile 1
CZ - Repubblica Ceca 1
FR - Francia 1
KR - Corea 1
LT - Lituania 1
MK - Macedonia 1
TW - Taiwan 1
Totale 7.846
Salva come PNG Salva come JPEG
Città #
Fairfield 934
Jacksonville 632
Woodbridge 438
Wilmington 369
Ashburn 368
Seattle 340
Cambridge 329
Houston 313
Chandler 306
Dearborn 284
Singapore 243
Beijing 140
Boardman 140
Princeton 134
Dublin 116
Ann Arbor 115
San Diego 78
Izmir 39
Norwalk 32
Ogden 29
Udine 26
Kunming 22
Santa Clara 21
Hefei 16
Nanjing 12
Des Moines 10
New York 10
Ottawa 10
Nanchang 9
Jinan 7
Chengdu 6
Grafing 6
Guangzhou 6
Toronto 4
Changsha 3
Fuzhou 3
Genova 3
Hebei 3
Shenyang 3
Andover 2
Baotou 2
Chongqing 2
Hangzhou 2
Helsinki 2
Jiaxing 2
Jinhua 2
Milan 2
Saint Petersburg 2
Wenzhou 2
Zhengzhou 2
Azzano Decimo 1
Brescia 1
Changchun 1
Chennai 1
Codroipo 1
Cornigliano 1
Guiyang 1
Harbin 1
Irving 1
Kamyshin 1
Kaunas 1
Padova 1
Phoenix 1
Porto Alegre 1
Prilep 1
Redmond 1
Shaoxing 1
Simi Valley 1
Southampton 1
Taipei 1
Tappahannock 1
Trieste 1
Washington 1
Wuhan 1
Xian 1
Totale 5.606
Salva come PNG Salva come JPEG
Nome #
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials 130
DOES BIOMODULATION OF 5-FLUOROURACIL IMPROVE RESULTS? 123
Taxane-induced nail changes: incidence, clinical presentation and outcome 118
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients 95
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer 95
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy 95
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG 94
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer 93
Chemotherapy: which drug and when? 91
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells 89
5-Fluorouracil may have different mechanisms of action depending on the dose schedule: clinical implications 88
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil 88
Irinotecan in combination with new agents 87
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer 87
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 87
Resistance to 5-fluorouracil and 5fluoro 2'deoxyuridine: mechanisms and clinical implications 86
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial 86
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy 85
Activity of continuous infusion 5-Fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-Fluorouracil 85
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC) 85
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study 85
The potential role of Tomudex in the treatment of advanced colorectal cancer 84
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer 84
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy 84
Fatigue: a main component of anemia symptomatology 82
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients 82
TUMOR MEASUREMENTS ON COMPUTED TOMOGRAPHIC IMAGES OF NON-SMALL CELL LUNG CANCER WERE SIMILAR AMONG CANCER PROFESSIONALS FROM DIFFERENT SPECIALTIES 82
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008 81
How uniform are postgraduate training programs in medical oncology in the European Union? 80
Urgent need for a new staging system in advanced colorectal cancer 80
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009 80
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules 80
Dacarbazine and Fotemustine in Advanced Colorectal Cancer 78
Bevacizumab plus fluorouracil: the value of being part of a developing story 78
Optimal treatment of metastatic colorectal cancer 78
Current controversies in the adjuvant therapy of colon cancer 77
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer 77
Tamoxifen-induced total alopecia 77
Current strategies to reduce cisplatin toxicity 76
Determinants of sensitivity and resistance to fluoropyrimidines 76
Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas 76
Informed decisions regarding microsatellite instability testing: need for an intention-to-screen analysis 76
Sequential chemotherapy with Paclitaxel plus Cisplatin, followed by Vinorelbine, followed by Gemcitabine in advanced non-small cell lung cancer: an Alpe Adria Thoracic Oncology Multidisciplinary group study (ATOM 001) 76
Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months? 75
Fluorouracil in colorectal cancer: a tale of two drugs. Implications for biochemical modulation 75
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab 75
Studies on hemopoietic stem cells in mice treated with testosterone propionate and anticancer drugs 74
Highlights from the 2008 Gastrointestinal Cancers Symposium 73
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group 73
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008 72
Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer 72
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer 71
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials 71
Molecular markers of chemotherapy in advanced colorectal cancer: back to square one 71
Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval 71
Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective 70
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma 70
SCHEDULE-SELECTIVE BIOCHEMICAL MODULATION OF 5-FLUOROURACIL IN ADVANCED COLORECTAL CANCER: A MULTICENTRIC PHASE II STUDY 70
Current issues in adjuvant treatment of stage II colon cancer 69
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials 69
Scheduling of fluorouracil: a forget-me-not in the jungle of doublets 67
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy 66
Improved therapeutic index of cisplatin with procaine HCl 66
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007 64
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer 64
Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine 63
A randomized trial of 5-fluorouracil alone vs 5-FU and high dose leucovorin in untreated advanced colorectal cancer patients 60
Phase II study of 5-fluorouracil + leucovorin and interferon alpha 2 b in advanced colorectal cancer 59
The medical treatment of advanced colorectal 59
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal 57
Role of oxaliplatin in the treatment of colorectal neoplasms 55
Activity of 4'Epi-doxorubicin on normal haemopoietic precursor cells in mice 55
Sensivity of spleen colony forming units to chronic administration of Bleomycin. Bogliolo G., Massa G., Sobrero A., and Pannacciulli I. British Journal of Cancer 40: 489, 1979. 55
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium 52
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) 51
Prospective randomized trial comparing fluorouracil versus doxifluorouridine for the treatment of advanced colorectal cancer 50
Biochemical determinants of antineoplastic activity of fluoropyrimidines 47
The clinical management of early and advanced colorectal cancer 46
Clinical aspects of drug resistance 46
LE ANEMIE 46
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Liver Metastases Workshop 45
Chemosensitivity of human tumor clonogenic cells simultaneously assayed in agar diffusion chambers and in a two-layer agar culture system 45
Methotrexate resistant cells as target for selective chemotherapy 44
The neo-adjuvant, surgical and adjuvant treatment of gastric 43
Adjuvant treatment of colorectal cancer in the elderly 43
schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer : A randomized study 42
Decreased folylpolyglutamate synthetase expression : a novel mechanism of fluorouracil resistance 41
Effects of high dose methotrexate and leucovorin on murine haemopoietic stem cells 40
Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine 39
PROTOCOLLI DI CHEMIOTERAPIA ANTINEOPLASTICA 38
Uptake and metabolism of 5-8-dideazaisofolic acid in human colon cancer cells 37
Randomized comparison of. weekly bolus five-fluorouracil with or without leucovorin in metastatic colorectal carcinoma 37
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting 37
Last news from ASCO 2000 in the topic of colorectal cancer 36
Superiority of twice daily vs once daily oral methylprednisolone in combination with ondansetron in the prevention of delayed emesis due to moderately and highly emetogenic chemotherapy. 36
Very high dose cisplatinum (450 mg/sqm) in an infant with rhabdomyosarcoma 35
Talking Tomudex: introduction 35
Surgical resection of gastrointestinal stromal tumor after treatment with imatinib: clinical case 35
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies 35
Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2 34
Totale 6.842
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.464
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.464
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.303 0 0 0 398 197 447 267 333 198 242 47 174
2020/20211.509 25 185 33 204 42 185 71 207 293 45 173 46
2021/2022868 28 109 14 75 20 31 43 66 15 165 137 165
2022/2023718 138 42 9 76 65 227 0 39 93 7 9 13
2023/2024162 29 8 3 3 16 24 1 11 43 0 0 24
2024/2025456 38 154 207 57 0 0 0 0 0 0 0 0
Totale 7.863